Storia in 2 fonti

Oorja, run by Acceleron veterans, launches to make new fibrosis drugs

The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring in people with idiopathic pulmonary fibrosis.

Raccontata da

endpoints.news

biopharmadive.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 mesi fa

Oorja, run by Acceleron veterans, launches to make new fibrosis drugs

The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring in people with idiopathic pulmonary fibrosis.

originale

endpoints.news1 mesi fa

Exclusive: Acceleron leaders and Westlake jumpstart new IPF biotech

On Tuesday, Oorja Bio launched with a $30 million Series A round all from Westlake BioPartners to study a new treatment for idiopathic pulmonary fibrosis.

Leggi questa versione → originale

Timeline cronologica

martedì 19 maggio 2026·endpoints.news
Exclusive: Acceleron leaders and Westlake jumpstart new IPF biotech
On Tuesday, Oorja Bio launched with a $30 million Series A round all from Westlake BioPartners to study a new treatment for idiopathic pulmonary fibrosis.
mercoledì 20 maggio 2026·biopharmadive.com
Oorja, run by Acceleron veterans, launches to make new fibrosis drugs
The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring in people with idiopathic pulmonary fibrosis.